Publications by authors named "Somkit Penpattanagul"
Introduction: This study aimed to compare the cost utility of concurrent chemoradiation (CCRT) to CCRT followed by adjuvant chemotherapy (CCRT/ACT) in locally advanced cervical cancer (LACC) using provider and societal viewpoints.
Methods: Data from our trial which was a multi-centre study evaluating the efficacy of ACT compared to CCRT/ACT were entered into a decision tree model. The data included clinical probability, direct medical and non-medical costs, and utility obtained from the patients.
A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
J Gynecol Oncol
July 2019
Article Synopsis
- The study aimed to evaluate the effectiveness of adding adjuvant chemotherapy (ACT) after standard concurrent chemoradiation therapy (CCRT) in patients with locally advanced cervical cancer.
- No significant difference in response rates or survival outcomes was observed between patients who received only CCRT and those who also received ACT, although systemic recurrences were lower in the ACT group.
- The findings suggest that adding ACT does not enhance overall treatment effectiveness compared to CCRT alone, despite some benefits in reducing systemic recurrences.
Objective: To compare the efficacy and toxicity of pelvic radiotherapy with concomitant cisplatin plus fluorouracil versus cisplatin alone in patients with locally advanced squamous cell cervical cancer.
Material And Method: Twenty women with squamous cell cervical cancer were randomly assigned to receive ether standard whole pelvic radiotherapy with concurrent cisplatin and fluorouracil infusion every 4 weeks or the same radiotherapy with concurrent cisplatin every 1 week. The primary endpoint was the response rate.
Objective: To evaluate the role of WF10-immunotherapy in reducing oro-pharyngeal complications in head and neck cancer chemoradiotherapy.
Material And Method: Thirteen patients were enrolled and assigned either to WF10- (n = 6) or control group (n = 7). After completion of their initial (neoadjuvant) chemotherapy, patients received WF10 intravenous infusions at 0.